Given the association of plaque stabilization and regression with LDL levels, it was logical to assume that the greater, immediate LDL reduction provided by the PCSK9 inhibitor use could greatly influence atherosclerosis progression, as was initially hypothesized in ACS patients [107]. Here, PCSK9 is linked to atherosclerosis.